Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5281715
Max Phase: Preclinical
Molecular Formula: C62H48N4O8S2
Molecular Weight: 1041.22
Associated Items:
ID: ALA5281715
Max Phase: Preclinical
Molecular Formula: C62H48N4O8S2
Molecular Weight: 1041.22
Associated Items:
Canonical SMILES: C=CCC/C=C/c1ccc2oc(=O)c(-c3csc(N4C(=O)c5ccc6c7c(ccc(c57)C4=O)C(=O)N(c4nc(-c5cc7c(/C=C/CCC=C)c(/C=C/CCC=C)ccc7oc5=O)cs4)C6=O)n3)cc2c1/C=C/CCC=C
Standard InChI: InChI=1S/C62H48N4O8S2/c1-5-9-13-17-21-37-25-31-51-45(39(37)23-19-15-11-7-3)33-47(59(71)73-51)49-35-75-61(63-49)65-55(67)41-27-29-43-54-44(30-28-42(53(41)54)56(65)68)58(70)66(57(43)69)62-64-50(36-76-62)48-34-46-40(24-20-16-12-8-4)38(22-18-14-10-6-2)26-32-52(46)74-60(48)72/h5-8,17-36H,1-4,9-16H2/b21-17+,22-18+,23-19+,24-20+
Standard InChI Key: GICSWUNVNYLZRU-OKNOEDMOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1041.22 | Molecular Weight (Monoisotopic): 1040.2914 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Tomczyk MD, Walczak KZ.. (2018) l,8-Naphthalimide based DNA intercalators and anticancer agents. A systematic review from 2007 to 2017., 159 [PMID:30312931] [10.1016/j.ejmech.2018.09.055] |
Source(1):